



2018-2019
BOARD OF DIRECTORS

PRESIDENT

Michele P. Calos, PhD
Stanford University School of Medicine

PRESIDENT ELECT

Guangping Gao, PhD
University of Massachusetts Medical
School

VICE PRESIDENT

Stephen J. Russell, MD, PhD
Mayo Clinic

SECRETARY

David V. Schaffer, PhD
University of California Berkeley

TREASURER

Paula M. Cannon, PhD
University of Southern California

DIRECTORS

Jennifer E. Adair, PhD
Fred Hutchinson Cancer Research Center

Alessandra Biffi, MD
Dana-Farber Cancer Institute

Paloma H. Giangrande, PhD
University of Iowa

Stephen L. Hart, PhD
UCL Great Ormond Street Institute of
Child Health

J. Keith Joung, MD, PhD
Massachusetts General Hospital

Richard Morgan, PhD
bluebird bio

Matthew H. Porteus, MD, PhD
Stanford University School of Medicine

Isabelle Riviere, PhD
Memorial Sloan-Kettering Cancer Center

Rachel Salzman, DVM
ALD Connect

EDITOR-IN-CHIEF

Seppo Yla-Herttuala, MD, PhD, FESC
University of Eastern Finland

EXECUTIVE DIRECTOR

David M. Barrett, JD

June 27, 2018

The Honorable Timothy E. Scott
Committee on Health, Education, Labor and Pensions
717 Hart Senate Office Building
Washington, DC 20510

Dear Senator Scott:

The American Society of Gene & Cell Therapy (ASGCT) appreciates your role in the inclusion of Section 605 to the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 (PAHPA), S. 2852. The Society supports this provision, calling for a meeting within a year from enactment to discuss the potential role that genomic engineering technologies, including gene editing, may have in advancing national health security.

ASGCT is a nonprofit professional membership organization comprised of more than 2,900 scientists, physicians, and other professionals working in gene and cell therapy. The Society is dedicated to advancing the knowledge of gene and cell therapies to alleviate human disease. Though ASGCT members focus primarily on human therapeutic applications of gene editing, the Society recognizes that this technology has the potential to contribute to additional societal benefits, which may include increasing food security and human health security. For example, gene editing could boost the ability to manage disease threats and develop counter-measures to biological weapons.¹

As stated in the proceedings from an October 2017 international workshop on the security implications of genome editing, subsequent work will be required at the national, regional, and international levels to develop recommendations on these topics. Genome editing has the potential for both great positive effects on societal priorities and for inadvertent or intentional misuse. Balanced discussion of the benefits and risks of the technology among relevant stakeholders includes assessment of whether and how intentional misuse could occur and methods for prevention, preparation, and mitigation.¹ ASGCT acknowledges the need for continuing this conversation on a national level, as Section 605 of PAHPA would do.

ASGCT is particularly supportive of the language that calls for inclusion of representatives from academic, private, and non-profit entities with expertise in genome engineering technologies, biopharmaceuticals, medicine, or bio defense, and other relevant stakeholders in such a meeting. Including scientific researchers in these deliberations is extremely important because they are able to utilize their expertise to assess scientific feasibility of the types of activities that may pose concern, manage threats, or offer counter-measure solutions. Following its enactment, ASGCT respectfully requests the opportunity to participate in such a stakeholder meeting.

Sincerely,

David M. Barrett, JD
Executive Director

1. Fears, R. (2017, 11-13 October). *Assessing the security implications of genome editing technology: Report of an international workshop*, Herrenhausen, Germany. Trieste, Italy: The InterAcademy Partnership.